| Year |
Citation |
Score |
| 2023 |
Kupershmidt L, Youdim MBH. The Neuroprotective Activities of the Novel Multi-Target Iron-Chelators in Models of Alzheimer's Disease, Amyotrophic Lateral Sclerosis and Aging. Cells. 12. PMID 36899898 DOI: 10.3390/cells12050763 |
0.313 |
|
| 2018 |
Youdim MBH. Monoamine oxidase inhibitors, and iron chelators in depressive illness and neurodegenerative diseases. Journal of Neural Transmission (Vienna, Austria : 1996). 125: 1719-1733. PMID 30341696 DOI: 10.1007/s00702-018-1942-9 |
0.371 |
|
| 2015 |
Salkovic-Petrisic M, Knezovic A, Osmanovic-Barilar J, Smailovic U, Trkulja V, Riederer P, Amit T, Mandel S, Youdim MB. Multi-target iron-chelators improve memory loss in a rat model of sporadic Alzheimer's disease. Life Sciences. 136: 108-19. PMID 26159898 DOI: 10.1016/J.Lfs.2015.06.026 |
0.311 |
|
| 2015 |
Bar-Am O, Amit T, Kupershmidt L, Aluf Y, Mechlovich D, Kabha H, Danovitch L, Zurawski VR, Youdim MB, Weinreb O. Neuroprotective and neurorestorative activities of a novel iron chelator-brain selective monoamine oxidase-A/monoamine oxidase-B inhibitor in animal models of Parkinson's disease and aging. Neurobiology of Aging. 36: 1529-42. PMID 25499799 DOI: 10.1016/j.neurobiolaging.2014.10.026 |
0.36 |
|
| 2014 |
Youdim MB, Kupershmidt L, Amit T, Weinreb O. Promises of novel multi-target neuroprotective and neurorestorative drugs for Parkinson's disease. Parkinsonism & Related Disorders. 20: S132-6. PMID 24262165 DOI: 10.1016/S1353-8020(13)70032-4 |
0.311 |
|
| 2013 |
Weinreb O, Mandel S, Youdim MB, Amit T. Targeting dysregulation of brain iron homeostasis in Parkinson's disease by iron chelators. Free Radical Biology & Medicine. 62: 52-64. PMID 23376471 DOI: 10.1016/j.freeradbiomed.2013.01.017 |
0.35 |
|
| 2013 |
Pollak Y, Mechlovich D, Amit T, Bar-Am O, Manov I, Mandel SA, Weinreb O, Meyron-Holtz EG, Iancu TC, Youdim MB. Effects of novel neuroprotective and neurorestorative multifunctional drugs on iron chelation and glucose metabolism. Journal of Neural Transmission (Vienna, Austria : 1996). 120: 37-48. PMID 22446839 DOI: 10.1007/s00702-012-0795-x |
0.305 |
|
| 2012 |
Weinreb O, Amit T, Bar-Am O, Youdim MB. Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment. Current Drug Targets. 13: 483-94. PMID 22280345 DOI: 10.2174/138945012799499794 |
0.302 |
|
| 2012 |
Weinreb O, Amit T, Mandel S, Youdim MB. Novel therapeutic approach for neurodegenerative pathologies: multitarget iron-chelating drugs regulating hypoxia-inducible factor 1 signal transduction pathway. Neuro-Degenerative Diseases. 10: 112-5. PMID 22156453 DOI: 10.1159/000332597 |
0.33 |
|
| 2011 |
Sian-Hülsmann J, Mandel S, Youdim MB, Riederer P. The relevance of iron in the pathogenesis of Parkinson's disease. Journal of Neurochemistry. 118: 939-57. PMID 21138437 DOI: 10.1111/J.1471-4159.2010.07132.X |
0.33 |
|
| 2010 |
Zheng H, Youdim MB, Fridkin M. Selective acetylcholinesterase inhibitor activated by acetylcholinesterase releases an active chelator with neurorescuing and anti-amyloid activities. Acs Chemical Neuroscience. 1: 737-46. PMID 22778810 DOI: 10.1021/Cn100069C |
0.3 |
|
| 2010 |
Weinreb O, Amit T, Mandel S, Kupershmidt L, Youdim MB. Neuroprotective multifunctional iron chelators: from redox-sensitive process to novel therapeutic opportunities. Antioxidants & Redox Signaling. 13: 919-49. PMID 20095867 DOI: 10.1089/ars.2009.2929 |
0.3 |
|
| 2009 |
Kupershmidt L, Weinreb O, Amit T, Mandel S, Carri MT, Youdim MB. Neuroprotective and neuritogenic activities of novel multimodal iron-chelating drugs in motor-neuron-like NSC-34 cells and transgenic mouse model of amyotrophic lateral sclerosis. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 23: 3766-79. PMID 19638399 DOI: 10.1096/fj.09-130047 |
0.318 |
|
| 2008 |
Amit T, Avramovich-Tirosh Y, Youdim MB, Mandel S. Targeting multiple Alzheimer's disease etiologies with multimodal neuroprotective and neurorestorative iron chelators. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 22: 1296-305. PMID 18048580 DOI: 10.1096/fj.07-8627rev |
0.318 |
|
| 2007 |
Avramovich-Tirosh Y, Reznichenko L, Mit T, Zheng H, Fridkin M, Weinreb O, Mandel S, Youdim MB. Neurorescue activity, APP regulation and amyloid-beta peptide reduction by novel multi-functional brain permeable iron- chelating- antioxidants, M-30 and green tea polyphenol, EGCG. Current Alzheimer Research. 4: 403-11. PMID 17908043 DOI: 10.2174/156720507781788927 |
0.319 |
|
| 2007 |
Zhu W, Xie W, Pan T, Xu P, Fridkin M, Zheng H, Jankovic J, Youdim MB, Le W. Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable iron chelators. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 21: 3835-44. PMID 17690154 DOI: 10.1096/Fj.07-8386Com |
0.301 |
|
| 2007 |
Mandel S, Amit T, Bar-Am O, Youdim MB. Iron dysregulation in Alzheimer's disease: multimodal brain permeable iron chelating drugs, possessing neuroprotective-neurorescue and amyloid precursor protein-processing regulatory activities as therapeutic agents. Progress in Neurobiology. 82: 348-60. PMID 17659826 DOI: 10.1016/j.pneurobio.2007.06.001 |
0.309 |
|
| 2007 |
Youdim MB, Amit T, Bar-Am O, Weinreb O, Yogev-Falach M. Implications of co-morbidity for etiology and treatment of neurodegenerative diseases with multifunctional neuroprotective-neurorescue drugs; ladostigil. Neurotoxicity Research. 10: 181-92. PMID 17197368 DOI: 10.1007/BF03033355 |
0.324 |
|
| 2007 |
Berg D, Youdim MB. Role of iron in neurodegenerative disorders. Topics in Magnetic Resonance Imaging : Tmri. 17: 5-17. PMID 17179893 DOI: 10.1097/01.rmr.0000245461.90406.ad |
0.323 |
|
| 2007 |
Youdim MB. The path from anti Parkinson drug selegiline and rasagiline to multifunctional neuroprotective anti Alzheimer drugs ladostigil and m30. Current Alzheimer Research. 3: 541-50. PMID 17168653 DOI: 10.2174/156720506779025288 |
0.302 |
|
| 2007 |
Avramovich-Tirosh Y, Amit T, Bar-Am O, Zheng H, Fridkin M, Youdim MB. Therapeutic targets and potential of the novel brain- permeable multifunctional iron chelator-monoamine oxidase inhibitor drug, M-30, for the treatment of Alzheimer's disease. Journal of Neurochemistry. 100: 490-502. PMID 17144902 DOI: 10.1111/J.1471-4159.2006.04258.X |
0.308 |
|
| 2006 |
Gal S, Fridkin M, Amit T, Zheng H, Youdim MB. M30, a novel multifunctional neuroprotective drug with potent iron chelating and brain selective monoamine oxidase-ab inhibitory activity for Parkinson's disease. Journal of Neural Transmission. Supplementum. 447-56. PMID 17017567 DOI: 10.1007/978-3-211-45295-0_68 |
0.337 |
|
| 2006 |
Gerlach M, Double KL, Youdim MB, Riederer P. Potential sources of increased iron in the substantia nigra of parkinsonian patients. Journal of Neural Transmission. Supplementum. 133-42. PMID 17017520 DOI: 10.1007/978-3-211-45295-0_21 |
0.306 |
|
| 2006 |
Mandel S, Amit T, Reznichenko L, Weinreb O, Youdim MB. Green tea catechins as brain-permeable, natural iron chelators-antioxidants for the treatment of neurodegenerative disorders. Molecular Nutrition & Food Research. 50: 229-34. PMID 16470637 DOI: 10.1002/mnfr.200500156 |
0.33 |
|
| 2005 |
Gal S, Zheng H, Fridkin M, Youdim MB. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion. Journal of Neurochemistry. 95: 79-88. PMID 16181414 DOI: 10.1111/J.1471-4159.2005.03341.X |
0.341 |
|
| 2005 |
Zheng H, Gal S, Weiner LM, Bar-Am O, Warshawsky A, Fridkin M, Youdim MB. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition. Journal of Neurochemistry. 95: 68-78. PMID 16181413 DOI: 10.1111/J.1471-4159.2005.03340.X |
0.365 |
|
| 2005 |
Mandel SA, Avramovich-Tirosh Y, Reznichenko L, Zheng H, Weinreb O, Amit T, Youdim MB. Multifunctional activities of green tea catechins in neuroprotection. Modulation of cell survival genes, iron-dependent oxidative stress and PKC signaling pathway. Neuro-Signals. 14: 46-60. PMID 15956814 DOI: 10.1159/000085385 |
0.332 |
|
| 2005 |
Zheng H, Weiner LM, Bar-Am O, Epsztejn S, Cabantchik ZI, Warshawsky A, Youdim MB, Fridkin M. Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases. Bioorganic & Medicinal Chemistry. 13: 773-83. PMID 15653345 DOI: 10.1016/J.Bmc.2004.10.037 |
0.321 |
|
| 2005 |
Youdim MB, Fridkin M, Zheng H. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases. Mechanisms of Ageing and Development. 126: 317-26. PMID 15621213 DOI: 10.1016/J.Mad.2004.08.023 |
0.382 |
|
| 2004 |
Mandel S, Maor G, Youdim MB. Iron and alpha-synuclein in the substantia nigra of MPTP-treated mice: effect of neuroprotective drugs R-apomorphine and green tea polyphenol (-)-epigallocatechin-3-gallate. Journal of Molecular Neuroscience : Mn. 24: 401-16. PMID 15655262 DOI: 10.1385/JMN:24:3:401 |
0.332 |
|
| 2004 |
Zecca L, Youdim MB, Riederer P, Connor JR, Crichton RR. Iron, brain ageing and neurodegenerative disorders. Nature Reviews. Neuroscience. 5: 863-73. PMID 15496864 DOI: 10.1038/Nrn1537 |
0.326 |
|
| 2004 |
Youdim MBH, Fridkin M, Zheng H. Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases Journal of Neural Transmission. 111: 1455-1471. PMID 15480846 DOI: 10.1007/S00702-004-0143-X |
0.382 |
|
| 2004 |
Mandel S, Youdim MB. Catechin polyphenols: neurodegeneration and neuroprotection in neurodegenerative diseases. Free Radical Biology & Medicine. 37: 304-17. PMID 15223064 DOI: 10.1016/j.freeradbiomed.2004.04.012 |
0.308 |
|
| 2004 |
Youdim MB, Stephenson G, Ben Shachar D. Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28. Annals of the New York Academy of Sciences. 1012: 306-25. PMID 15105275 DOI: 10.1196/annals.1306.025 |
0.356 |
|
| 2004 |
Götz ME, Double K, Gerlach M, Youdim MBH, Riederer P. The relevance of iron in the pathogenesis of Parkinson's disease Annals of the New York Academy of Sciences. 1012: 193-208. PMID 15105267 DOI: 10.1196/annals.1306.017 |
0.326 |
|
| 2004 |
Shachar DB, Kahana N, Kampel V, Warshawsky A, Youdim MB. Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats. Neuropharmacology. 46: 254-63. PMID 14680763 DOI: 10.1016/j.neuropharm.2003.09.005 |
0.363 |
|
| 2003 |
Youdim MB. What have we learnt from CDNA microarray gene expression studies about the role of iron in MPTP induced neurodegeneration and Parkinson's disease? Journal of Neural Transmission. Supplementum. 73-88. PMID 12946050 DOI: 10.1007/978-3-7091-0643-3_5 |
0.332 |
|
| 2002 |
Berg D, Gerlach M, Youdim MBH, Double KL, Zecca L, Riederer P, Becker G. Brain iron pathways and their relevance to Parkinson's disease Journal of Neurochemistry. 80: 719-719. DOI: 10.1046/j.0022-3042.2001.00742.x |
0.307 |
|
| 2001 |
Berg D, Gerlach M, Youdim MB, Double KL, Zecca L, Riederer P, Becker G. Brain iron pathways and their relevance to Parkinson's disease. Journal of Neurochemistry. 79: 225-36. PMID 11677250 DOI: 10.1046/j.1471-4159.2001.00608.x |
0.319 |
|
| 2000 |
Double KL, Gerlach M, Youdim MB, Riederer P. Impaired iron homeostasis in Parkinson's disease. Journal of Neural Transmission. Supplementum. 37-58. PMID 11205155 DOI: 10.1007/978-3-7091-6301-6_3 |
0.325 |
|
| 1999 |
Youdim MB, Grünblatt E, Mandel S. The pivotal role of iron in NF-kappa B activation and nigrostriatal dopaminergic neurodegeneration. Prospects for neuroprotection in Parkinson's disease with iron chelators. Annals of the New York Academy of Sciences. 890: 7-25. PMID 10668410 DOI: 10.1111/J.1749-6632.1999.Tb07977.X |
0.35 |
|
| 1999 |
Grünblatt E, Mandel S, Gassen M, Youdim MB. Potent neuroprotective and antioxidant activity of apomorphine in MPTP and 6-hydroxydopamine induced neurotoxicity. Journal of Neural Transmission. Supplementum. 55: 57-70. PMID 10335493 DOI: 10.1007/978-3-7091-6369-6_6 |
0.307 |
|
| 1997 |
Gassen M, Youdim MB. The potential role of iron chelators in the treatment of Parkinson's disease and related neurological disorders. Pharmacology & Toxicology. 80: 159-66. PMID 9140134 DOI: 10.1111/J.1600-0773.1997.TB00390.X |
0.328 |
|
| 1997 |
Gassen M, Glinka Y, Pinchasi B, Youdim MB. Apomorphine is a highly potent free radical scavenger in rat brain mitochondrial fraction. European Journal of Pharmacology. 308: 219-25. PMID 8840135 DOI: 10.1016/0014-2999(96)00291-9 |
0.302 |
|
| 1994 |
Ben-Shachar D, Livne E, Spanier I, Leenders KL, Youdim MB. Typical and atypical neuroleptics induce alteration in blood-brain barrier and brain 59FeCl3 uptake. Journal of Neurochemistry. 62: 1112-8. PMID 7906714 DOI: 10.1046/j.1471-4159.1994.62031112.x |
0.329 |
|
| 1993 |
Ben-Shachar D, Youdim MB. Iron, melanin and dopamine interaction: relevance to Parkinson's disease. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 17: 139-50. PMID 8416600 DOI: 10.1016/0278-5846(93)90038-T |
0.321 |
|
| 1991 |
Ben-Shachar D, Riederer P, Youdim MBH. Iron‐Melanin Interaction and Lipid Peroxidation: Implications for Parkinson's Disease Journal of Neurochemistry. 57: 1609-1614. PMID 1919577 DOI: 10.1111/J.1471-4159.1991.Tb06358.X |
0.324 |
|
| 1991 |
Sofic E, Paulus W, Jellinger K, Riederer P, Youdim MBH. Selective increase of iron in substantia nigra zona compacta of parkinsonian brains. Journal of Neurochemistry. 56: 978-982. PMID 1704426 DOI: 10.1111/J.1471-4159.1991.Tb02017.X |
0.304 |
|
| 1990 |
Jellinger K, Paulus W, Grundke-Iqbal I, Riederer P, Youdim MB. Brain iron and ferritin in Parkinson's and Alzheimer's diseases. Journal of Neural Transmission. Parkinson's Disease and Dementia Section. 2: 327-40. PMID 2078310 |
0.31 |
|
| 1986 |
Ben-Shachar D, Ashkenazi R, Youdim MB. Long-term consequence of early iron-deficiency on dopaminergic neurotransmission in rats. International Journal of Developmental Neuroscience : the Official Journal of the International Society For Developmental Neuroscience. 4: 81-8. PMID 2844061 DOI: 10.1016/0736-5748(86)90019-5 |
0.33 |
|
| 1982 |
Ashkenazi R, Ben-Shachar D, Youdim MB. Nutritional iron and dopamine binding sites in the rat brain. Pharmacology, Biochemistry, and Behavior. 17: 43-7. PMID 7184034 DOI: 10.1016/0091-3057(82)90509-3 |
0.313 |
|
| 1981 |
Youdim MB, Yehuda S, Ben-Uriah Y. Iron deficiency-induced circadian rhythm reversal of dopaminergic-mediated behaviours and thermoregulation in rats. European Journal of Pharmacology. 74: 295-301. PMID 7197630 DOI: 10.1016/0014-2999(81)90048-0 |
0.334 |
|
| 1971 |
Papeschi R, Sourkes TL, Youdim MBH. The effect of yohimbine on brain serotonin metabolism, motor behavior and body temperature of the rat European Journal of Pharmacology. 15: 318-326. PMID 5170178 DOI: 10.1016/0014-2999(71)90098-7 |
0.456 |
|
| 1970 |
Symes AL, Sourkes TL, Youdim MB, Gregoriadis G, Birnbaum H. Decreased monoamine oxidase activity in liver of iron-deficient rats. Canadian Journal of Biochemistry. 47: 999-1002. PMID 5353933 DOI: 10.1139/O69-160 |
0.527 |
|
| Show low-probability matches. |